---
title: "Silicon Labs | 8-K: FY2027 Q2 Revenue Misses Estimate at USD 228.19 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295577429.md"
datetime: "2026-08-11T20:37:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295577429.md)
  - [en](https://longbridge.com/en/news/295577429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295577429.md)
generator: "portal-rs"
---

# Silicon Labs | 8-K: FY2027 Q2 Revenue Misses Estimate at USD 228.19 M

Revenue: As of FY2027 Q2, the actual value is USD 228.19 M, missing the estimate of USD 266.3 M.

EPS: As of FY2027 Q2, the actual value is USD -0.32, missing the estimate of USD -0.01.

EBIT: As of FY2027 Q2, the actual value is USD -8.177 M.

### Second Quarter 2026 Financial Highlights (Ended July 4, 2026)

#### Revenue

Silicon Laboratories Inc. reported total revenue of $228 million, representing an 18% increase year-over-year. Industrial & Commercial segment revenue was $135 million, up 23% year-over-year. Home & Life segment revenue was $93 million, up 12% year-over-year. Medical revenue achieved a record in the quarter, increasing 78% year-over-year. 

#### GAAP Operational Metrics

-   GAAP gross margin was 61.6%.
-   GAAP operating expenses totaled $151 million.
-   GAAP operating loss was -$11 million.
-   Net loss was -$10,592 thousand for the three months ended July 4, 2026, compared to -$21,817 thousand for the three months ended July 5, 2025.

#### Non-GAAP Operational Metrics

-   Non-GAAP gross margin was 61.9%.
-   Non-GAAP operating expenses were $114 million.
-   Non-GAAP operating income was $27 million.

### Six Months Ended July 4, 2026 Financial Performance

#### GAAP Operational Metrics (Six Months)

-   Gross profit was $267,672 thousand, compared to $205,886 thousand for the six months ended July 5, 2025.
-   Operating expenses were $295,420 thousand, compared to $260,833 thousand for the six months ended July 5, 2025.
-   Operating loss was -$27,748 thousand, compared to -$54,947 thousand for the six months ended July 5, 2025.
-   Net loss was -$26,489 thousand, compared to -$52,287 thousand for the six months ended July 5, 2025.

#### Cash Flow (Six Months Ended July 4, 2026)

-   Net cash used in operating activities was -$9,578 thousand, compared to net cash provided by operating activities of $53,036 thousand for the six months ended July 5, 2025.
-   Net cash provided by investing activities was $27,238 thousand, compared to net cash used in investing activities of -$14,051 thousand for the six months ended July 5, 2025.
-   Net cash used in financing activities was -$19,691 thousand, compared to -$6,133 thousand for the six months ended July 5, 2025.
-   Cash and cash equivalents at the end of the period were $362,191 thousand, representing a decrease of -$2,031 thousand from the beginning of the period.

#### Balance Sheet Highlights (As of July 4, 2026)

-   Cash and cash equivalents were $362,191 thousand, slightly down from $364,222 thousand as of January 3, 2026.
-   Inventories increased to $123,340 thousand from $95,566 thousand as of January 3, 2026.
-   Total liabilities were $158,254 thousand, down from $174,899 thousand as of January 3, 2026.

#### Operational Metrics and Business Indicators

-   Bookings and new orders accelerated during the quarter.
-   Inventory at both distributors and end customers declined.
-   Total opportunity funnel and design wins materially accelerated, reinforcing a durable growth trajectory.

#### Outlook / Guidance

Silicon Laboratories Inc. has suspended providing forward-looking guidance. This suspension is due to the announced pending acquisition by Texas Instruments.

### Related Stocks

- [SLAB.US](https://longbridge.com/en/quote/SLAB.US.md)

## Related News & Research

- [Should Silicon Labs’ Grant-Backed Austin R&D Expansion Require Action From Silicon Laboratories (SLAB) Investors?](https://longbridge.com/en/news/298104738.md)
- [Susquehanna Fundamental Investments LLC Acquires 15,128 Shares of Silicon Laboratories, Inc. $SLAB](https://longbridge.com/en/news/297631359.md)
- [Empire Q1 GAAP EPS of $1.04](https://longbridge.com/en/news/298612302.md)
- [InMed Pharmaceuticals GAAP EPS of -$3.12](https://longbridge.com/en/news/298502732.md)
- [Coffee Holding GAAP EPS of $0.35, revenue of $21.69M](https://longbridge.com/en/news/298743579.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**